Views: 1,338 | Downloads:
21
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Anti-thrombotic and Anticoagulant Treatment in Interventional Cardiology
Mahanonda N 
Efforts to improve Percutaneous Transluminal Coronary Angioplasty (PTCA) have resulted
in the usage of new antiplatelets, and antithrombotic agents. These new agents may increase
bleeding complications. However, EPIC, EPILOG and CAPTURE trials showed benefits of 7E3,
a GPIIb/IIIa platelets receptor blocker, in high risk PTCA patients. On the other hand, direct
thrombin inhibitors, Hirudin and Hirulog, did not clearly show any benefit when compared to
heparin in patients with unstable angina undergoing PTCA. Combination of oral antiplatelets,
ticlopidine and aspirin, is widely utilized following stent implantation. However, its benefit over
aspirin alone has not been demonstrated. This article aims to review mechanisms and benefits of
these new agents in cardiovascular field.
in the usage of new antiplatelets, and antithrombotic agents. These new agents may increase
bleeding complications. However, EPIC, EPILOG and CAPTURE trials showed benefits of 7E3,
a GPIIb/IIIa platelets receptor blocker, in high risk PTCA patients. On the other hand, direct
thrombin inhibitors, Hirudin and Hirulog, did not clearly show any benefit when compared to
heparin in patients with unstable angina undergoing PTCA. Combination of oral antiplatelets,
ticlopidine and aspirin, is widely utilized following stent implantation. However, its benefit over
aspirin alone has not been demonstrated. This article aims to review mechanisms and benefits of
these new agents in cardiovascular field.
Download:
PDF